Latest Rosiglitazone Stories

BARCELONA (Reuters) - Patients with type 2 diabetes who have already suffered a first stroke have 47 percent less risk of having a second one if they take Takeda Pharmaceutical Co. Ltd's drug Actos, researchers said on Sunday. The finding, presented at the World Congress of Cardiology, is the latest sign that the oral anti-diabetic medicine provides benefits beyond lowering blood sugar levels. Dr Robert Wilcox of University Hospital, Nottingham, England, said adding Actos to standard...

By Maggie Fox, Health and Science Correspondent WASHINGTON (Reuters) - Diabetes and pre-diabetic conditions appear to worsen the risk of Alzheimer's disease but drugs that help regulate blood sugar may help patients with dementia as well, researchers report. Several studies presented at a meeting in Madrid, Spain, this week show that patients who take some of the drugs commonly prescribed to type-2 diabetes were less likely to have Alzheimer's disease. The findings worried Alzheimer's...

By Maggie Fox, Health and Science Correspondent WASHINGTON (Reuters) - Diabetes and pre-diabetic conditions appear to worsen the risk of Alzheimer's disease but drugs that help regulate blood sugar may help patients with dementia as well, researchers report. Several studies presented at a meeting in Madrid, Spain, this week show that patients who take some of the drugs commonly prescribed to type-2 diabetes were less likely to have Alzheimer's disease. The findings worried Alzheimer's...

By Maggie Fox, Health and Science CorrespondentWASHINGTON (Reuters) - Diabetes and pre-diabetic conditions appear to worsen the risk of Alzheimer's disease but drugs that help regulate blood sugar may help patients with dementia as well, researchers report.Several studies presented at a meeting in Madrid, Spain, this week show that patients who take some of the drugs commonly prescribed to type-2 diabetes were less likely to have Alzheimer's disease.The findings worried Alzheimer's experts,...

By Will Boggs, MD NEW YORK (Reuters Health) - Better metabolic control of type 2 diabetes can lead to improved "working memory" -- the type of memory people use to keep information in their minds for short-periods of time and to complete day-to-day activities. "Many of the patients with type 2 diabetes may have evidence of mild cognitive dysfunction," Dr. Christopher M. Ryan, from University of Pittsburgh School of Medicine, told Reuters Health. "Improving metabolic control and...

LONDON (Agence de Presse Medicale) - The European Medicines Agency's scientific committee will investigate a possible link between glitazone therapies and macular oedema, the agency announced on Thursday. The CHMP investigation comes after the EMEA received reports of cases of macular oedema in patients taking GlaxoSmithKline's Avandia/Avandamet (rosiglitazone) and Takeda and Lilly's Actos (pioglitazone). A spokeswoman for the EMEA told APM that since 2000 the agency had been alerted...

By Susan Heavey WASHINGTON (Reuters) - An experimental diabetes drug that may increase the risk of congestive heart failure and death should not be allowed on the market despite initial support from U.S. regulators, a consumer group said on Monday. Public Citizen's Health Research Group called on the U.S. Food and Drug Administration to hold off approving Pargluva, made by Bristol-Myers Squibb Co. and Merck & Co Inc., without "at the very least" a five-year clinical safety study. The...

By Susan HeaveyWASHINGTON -- An experimental diabetes drug that may increase the risk of congestive heart failure and death should not be allowed on the market despite initial support from U.S. regulators, a consumer group said on Monday.Public Citizen's Health Research Group called on the U.S. Food and Drug Administration to hold off approving Pargluva, made by Bristol-Myers Squibb Co. and Merck & Co Inc., without "at the very least" a five-year clinical safety study.The fate...

By Ransdell Pierson and Bill Berkrot DALLAS (Reuters) - A diabetes drug sold by Takeda Pharmaceutical Co. and Eli Lilly and Co. significantly cut the rate of a second heart attack compared with a placebo in high-risk patients with type-2 diabetes, a study reported on Wednesday found. The data come from a secondary analysis of a failed trial of the drug Actos reported in September, which had a more ambitious main goal of preventing a wide range of adverse heart events, including death,...

DALLAS (Reuters) - A diabetes drug sold by Takeda Pharmaceutical Co. and Eli Lilly and Co. significantly cut the rate of a second heart attack compared with a placebo in high-risk patients with type-2 diabetes, a study reported on Wednesday found. The data come from a secondary analysis of a failed trial of the drug Actos reported in September, which had a more ambitious main goal of preventing a wider range of cardiovascular incidents, including death, stroke, and heart attack in...